益方生物科技（上海）有限公司是一家成立于2013年的创业型生物医药公司，致力于肿瘤，肿瘤免疫，代谢领域的新药研发，公司产品管线已包含肺癌、乳腺癌，肿瘤免疫和痛风等领域靶向治疗的小分子候选药物，同时公司也在积极开发其他肿瘤及免疫肿瘤靶点的药物。公司目前有四个自主研发的1类新药，分别在中、美两地进行临床一、二期试验。
益方的目标不仅是要让中国而且是要让全世界的患者从我们研发的新药中受益，与此同时，我们也在资本市场上获得认可（2017年获得奥博资本与礼来亚洲基金的投资），与他们的战略合作将为公司今后的方向打下坚实的基础，在未来的全球医药市场上获得快速发展。
益方的目标不仅是要让中国而且是要让全世界的患者从我们研发的新药中受益，与此同时，我们也在资本市场上获得认可（2017年获得奥博资本与礼来亚洲基金的投资），与他们的战略合作将为公司今后的方向打下坚实的基础，在未来的全球医药市场上获得快速发展。
Location: United States, New Jersey, Florham Park
Employees: 11-50
Total raised: $236M
Founded date: 2013
Investors 5
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | OrbiMed | orbimed.co... |
| - | Qiming Ven... | qimingvent... |
| 09.02.2022 | Matrix Par... | matrixpart... |
| 25.05.2021 | Qiming Ven... | qimingvc.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.09.2020 | Series D | $147M | Matrix Par... |
| 12.03.2019 | Series C | $70M | - |
| 31.05.2017 | Series B | $19M | - |
Mentions in press and media 9
| Date | Title | Description |
| 03.12.2024 | InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis | – D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics – SHANGHAI, Dec. 3, 2024 /PRNewswire/ -- InventisBio Co., Ltd. today announced promising results from a Phase 2 cli... |
| 29.09.2020 | InventisBio Raises $147M in Series D Financing | InventisBio, a Shangai, China-based clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, closed a $147m series D financing. The was led by Hillhouse affiliate GL Ventures, followed by ... |
| 27.09.2020 | InventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures | |
| 13.03.2019 | Term Sheet — Wednesday, March 13 | A BRIBERY RING Twitter is buzzing with news of the college admissions cheating scandal, in which more than 40 people have been accused for paying bribes to get their children into elite schools, including Georgetown, Stanford, UCLA, and Yal... |
| 12.03.2019 | Daily funding roundup - March 12th, 2019 | Oova raised $1M; Livly raised $10M; ZayZoon raised $15M; Cloudflare raised $150M OOVA: Oova is a fertility diagnostic company that brings the accuracy of a clinic into your own home. Oova has raised $1 million in funding led by Special Situ... |
| 12.03.2019 | InventisBio Closes $70 Million USD Series C Financing | InventisBio Inc., a Shangai, China-based clinical stage biotech company, closed a $70m Series C financing. The round was co-led by Advantech Capital and CMBI, followed by Pudong Innotek and existing investors Lilly Asia Venture (LAV) and Or... |
| 31.05.2017 | InventisBio Raises US$19M in Series B Financing | InventisBio, a Shangai, China-based biotech company dedicated to the discovery and development of novel medicines, raised US$19m in Series B funding. The round was led by OrbiMed Asia Partners with participation from Lilly Asia Ventures (LA... |
| 31.05.2017 | Lilly, OrbiMed back China cancer upstart InventisBio in $19M series B | Shanghai-based cancer and gout biotech InventisBio has raised $19 million in a series B financing, just a year after its $11 million series A, with the cash injection being led by OrbiMed Asia Partners and original backer Lilly Asia Venture... |
| 31.05.2017 | Orbimed Asia leads $19m round in Chinese biotech startup InventisBio | Premium Shanghai-headquartered biotech startup InventisBio has raised $19 million in its Series B round of funding led by Orbimed Asia Partners, a healthcare-focused investment firm, the company said in a release. Continue reading this stor... |